179 related articles for article (PubMed ID: 8692130)
1. How valuable is prostate-specific antigen screening?
Handler S
Minn Med; 1996 Jun; 79(6):2. PubMed ID: 8692130
[No Abstract] [Full Text] [Related]
2. Does screening with prostate/specific antigen improve outcomes?
Ohrt D
Minn Med; 1996 Apr; 79(4):50-1. PubMed ID: 8637494
[No Abstract] [Full Text] [Related]
3. Prostate cancer: enthusiasm for screening.
Kaye KW
Med J Aust; 1995 May; 162(10):540-1. PubMed ID: 7539884
[No Abstract] [Full Text] [Related]
4. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Rosser CJ; Parker A
J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
[No Abstract] [Full Text] [Related]
5. PSA screening: the bottom line.
Elhilali MM
CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
[No Abstract] [Full Text] [Related]
6. Why PSA testing does have value.
Kirby M
Practitioner; 1997 Jul; 241(1576):363. PubMed ID: 9425708
[No Abstract] [Full Text] [Related]
7. Screening by the prostate-specific antigen test: what do the patients know?
Diefenbach PN; Ganz PA; Pawlow AJ; Guthrie D
J Cancer Educ; 1996; 11(1):39-44. PubMed ID: 8777154
[TBL] [Abstract][Full Text] [Related]
8. Best screening tests for prostate cancer.
Moul JW
West J Med; 1998 Aug; 169(2):109-10. PubMed ID: 9735692
[No Abstract] [Full Text] [Related]
9. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
Ito K
Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
[No Abstract] [Full Text] [Related]
10. [Mass screening for prostate cancer in Nagano].
Ishizuka O; Satoh T; Kobayashi S; Nishizawa O
Hinyokika Kiyo; 2001 Nov; 47(11):769-72. PubMed ID: 11771167
[TBL] [Abstract][Full Text] [Related]
11. Is PSA necessary after prostatectomy?
Kessenich CR
Nurse Pract; 2010 Jan; 35(1):10-1. PubMed ID: 20027017
[No Abstract] [Full Text] [Related]
12. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Stenman UH
Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
[No Abstract] [Full Text] [Related]
13. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?
Anast JW; Andriole GL; Bismar TA; Yan Y; Humphrey PA
Urology; 2004 Sep; 64(3):544-50. PubMed ID: 15351590
[TBL] [Abstract][Full Text] [Related]
14. Is an improved PSA screening test in sight?
Savage L
J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529
[No Abstract] [Full Text] [Related]
15. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
Shibata A
Cancer; 1999 Mar; 85(5):1208-10. PubMed ID: 10091812
[No Abstract] [Full Text] [Related]
16. [Legal (liability) aspects of PSA determination].
Mielke K
Urologe A; 2006 Jun; 45(6):756-65. PubMed ID: 16788794
[No Abstract] [Full Text] [Related]
17. [The use of prostate specific antigen in prostate cancer--prediction for treatment failure].
Egawa S
Nihon Rinsho; 2002 Dec; 60 Suppl 11():100-6. PubMed ID: 12599553
[No Abstract] [Full Text] [Related]
18. Efficacy vs effectiveness in prostate-specific antigen screening.
Albertsen PC
J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
[No Abstract] [Full Text] [Related]
19. Is screening for prostate cancer the current gold standard?--"no".
Kramer BS; Gohagan JK; Prorok PC
Eur J Cancer; 1997 Mar; 33(3):348-53. PubMed ID: 9155515
[No Abstract] [Full Text] [Related]
20. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
